Skip to content

Efficacy and safety of temporary pyloric dilatation by intraoperative PraBotulinum toxin A Injection for the prevention of delayed Gastric Emptying immediate after Pylorus Preserving Gastrectomy for gastric cancer

Efficacy and safety of temporary pyloric dilatation by intraoperative PraBotulinum toxin A Injection for the improvement of Gastric Emptying immediate after Pylorus Preserving Gastrectomy: Multicenter Prospective randomized controlled trial (BIGEPPG trial)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0004077
Enrollment
56
Registered
2019-06-20
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Procedure/Surgery : There is no difference in surgical technique between the two groups. In the experimental group, however, the injection of Nabota is performed on the pylorus during surgery. 1

Sponsors

Chung-Ang Univerisity Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Patient confirmed by gastric cancer due to histological examination ? Stomach cancer located at the mid-third of the stomach (The distal margin of stomach cancer at least 5 cm away far from the pylorus) ? Clinical stage was cT1N0M0 (EGD, CT, EUS) ? 20 year-old ~ 60 year-old ? Patients whose Eastern Cooperative Oncology Group performance status is 0 or 1 ? ASA score (American society of anesthesiology) Class I to III patients ? Before participating in the examination, please listen to the purpose and contents of the examination thoroughly and participate in this study according to the free will. The patient who signed the written consent of the institutional ethics review committee

Exclusion criteria

Exclusion criteria: ? the duodenal ulcer with pyloric anomalies ? there is another stomach lesion that can not be done with pylorus-preserving gastrectomy (synchronous gastric cancer, adenoma, etc.) ? Pylorus-preserving gastrectomy is not possible due to past past surgery ? Liver Cirrhosis ? The patient with chemotherapy or radiotherapy before surgery ? Patients who need combined resection due to other diseases (eg, gallstone disease) ? Patients who underwent surgery for other organ primary carcinomas within the last 5 years or who received chemotherapy or radiotherapy (excluding cured skin basal cell carcinoma and in situ cervical cancer) ? Vulnerable subjects (those who lack mental capacity , expectant mothers or those planning pregnancy) ? Patients who have participated in other clinical trials within the last 6 months or are currently participating ? Persons with a disease that may affect neuromuscular function such as myasthenia gravis, Eaton-Rambutton syndrome, amyotrophic axillary sclerosis, and motor neuropathy ? Those who have taken the following drugs within 4 weeks before screening - muscle relaxant: tuvocaralin system, mono trolene sodium, baclofen, etc. - Aminoglycoside antibiotics: gentamycin sulfate, neomycin sulfate, etc. - Other antibiotics: Dyes specinomycin, polyamicin, tetracycline, lincomycin, etc. - Anticholinergic agents: butyl scopolamine bromide, trihexyphenidyl hydrochloride, etc. - benzodiazepines and similar agents: diazepam, etiazolam, etc. - Benzamide medicines: thiaflide hydrochloride, sulpiride, etc. ? Any person who is allergic or sensitive to a clinical trial drug or its ingredients ? Pregnant women ? Other patients who were deemed unsuitable for participating in this study

Design outcomes

Primary

MeasureTime frame
Half life of Gastric emptying study

Secondary

MeasureTime frame
incidence of delayed gastric emptying;Body weight and Fat volume change on abdominal CT scan;Change of Hemoglobin, Protein, and Albumin;Postoperative QOL measurement (EORTC C30/STO22);Gross findings on gastroscopy by RGB criteria;Half life of Gastric emptying study

Countries

Korea, Republic of

Contacts

Public ContactJong Won Kim

Chung-Ang Univerisity Hospital

drholy@gmail.com+82-2-6299-1571

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026